Co-trimoxazole compared with sulfadoxine-pyrimethamine in the treatment of uncomplicated malaria in Kenyan children.
Sulfadoxine-pyrimethamine (SP) and co-trimoxazole were both effective in reducing fever, clearing parasitaemia and improving anaemia in children aged < 5 years with uncomplicated malaria in 2 Kenyan endemic sites, Oyugis in the west and Tiwi on the coast. We compared the efficacy of these 2 regimens (in May-July 1998) by evaluating clinical and parasitological responses over 14 days. The combined incidence of parasitological failure for the combined sites for co-trimoxazole was 14/123 (11%) and for SP 23/145 (16%) (RR 0.72, 95% confidence interval [CI] 0.31-1.46, P = 0.289). The 14-day clinical failure rate for the combined sites for co-trimoxazole was 4/123 (3.3%), and for SP 8/145 (5.5%), (RR 1.69, 95% CI 0.91-3.15, P = 0.129). The results indicate that the risk of treatment failure for the 2 regimens was similar. The antimalarial use of co-trimoxazole in uncomplicated malaria needs further investigation, since the 10-12-h elimination half-life of both components should reduce selective pressure for resistance. In addition, use of a 2-day high-dose course, tested previously, requires further study to demonstrate its efficacy.
Item Type | Article |
---|---|
Keywords | malaria, Plasmodium falciparum, chemotherapy, co-trimoxazole, sulfadoxine-pyrimethamine, children, Kenya, Plasmodium-falciparum, dihydrofolate-reductase, cotrimoxazole, resistance, Acute Disease, Antimalarials, therapeutic use, Child, Preschool, Coma, drug therapy, Comparative Study, Drug Combinations, Female, Fever, drug therapy, Human, Infant, Malaria, Falciparum, drug therapy, Male, Parasitemia, drug therapy, Pyrimethamine, therapeutic use, Sulfadoxine, therapeutic use, Support, Non-U.S. Gov't, Treatment Outcome, Trimethoprim-Sulfamethoxazole Combination, therapeutic use |
ISI | 173516800018 |